BBH VanEck Biotech ETF
- 176.610
- -1.485-0.83%
Regeneron Pharma Price Target Raised to $1200.00/Share From $1030.00 by TD Cowen
Vertex Pharmaceuticals Analyst Ratings
Regeneron Pharmaceuticals Analyst Ratings
Argenx Analyst Ratings
HSBC Adjusts Price Target on IQVIA to $290 From $280
BofA Securities Maintains IQVIA Holdings(IQV.US) With Buy Rating, Maintains Target Price $275
A Quick Look at Today's Ratings for IQVIA Holdings(IQV.US), With a Forecast Between $251 to $300
Oppenheimer Upgrades Argenx SE to Outperform From Perform, $546 Price Target
TD Cowen Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Raises Target Price to $1,200
Gilead Sciences (GILD) Receives a Buy From TD Cowen
Oppenheimer Upgrades Argenx SE(ARGX.US) to Buy Rating, Announces Target Price $546
Piper Sandler Maintains Biogen(BIIB.US) With Buy Rating, Maintains Target Price $313
Piper Sandler Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Vertex Pharmaceuticals(VRTX.US) With Buy Rating, Raises Target Price to $500
TD Cowen Maintains Gilead Sciences(GILD.US) With Buy Rating, Maintains Target Price $85
TD Cowen Maintains Amgen(AMGN.US) With Buy Rating, Maintains Target Price $360
IQVIA Holdings Price Target Raised to $251.00/Share From $235.00 by Baird
Piper Sandler Maintains Regeneron Pharmaceuticals(REGN.US) With Buy Rating, Maintains Target Price $1,166
IQVIA Hldgs Analyst Ratings
Evercore ISI Adjusts Price Target on IQVIA Holdings to $270 From $230, Maintains Outperform Rating